Team discovers new mechanism allowing tumor cells to escape immune surve

March 18, 2014, H. Lee Moffitt Cancer Center & Research Institute

The immune system plays a pivotal role in targeting cancer cells for destruction. However, tumor cells are smart and have developed ways to avoid immune detection. A collaborative team of researchers at Moffitt Cancer Center recently discovered a novel mechanism that lung cancer cells use to block detection by a type of immune cell called a natural killer cell (NK cell).

NK cells find and destroy virally infected cells and also play an important role in detecting and killing tumor cells. However, tumors produce high amounts of a protein called Transforming Growth Factor-Beta (TGF-β) that suppresses the activity of NK cells.

A team of researchers led by Julie Y. Djeu, Ph.D., associate center director of education and training at Moffitt, discovered that TGF-β produced by tumor cells causes NK cells to make high levels of a molecule called microRNA-183 (miR-183). MicroRNAs are important regulators of gene expression. They bind to genetic components called RNA and target them for destruction. Scientists discovered in the early 2000s that deregulation of microRNAs can lead to the development of cancer.

Djeu's laboratory reported that miR-183 binds to the RNA for a protein called DAP12, resulting in significantly lower levels of DAP12 in NK cells. DAP12 plays a critical role in activating the NK cells' cytotoxic pathways; therefore, lower levels of DAP12 in NK cells results in a reduced ability to target .

The researchers confirmed their observations by studying tissue from lung cancer tumors. They discovered that in normal tissue NK cells had moderate to high levels of DAP12; however, the NK cells within or surrounding the tumor had significantly reduced levels of DAP12.

Djeu explained that, "The world of microRNAs is just being explored, especially within , to identify what they control. How microRNAs might intercept in cancer is unknown and we were able to provide insight into a critical means by which cancer cells exploit miR-183 to dampen ."

Lung cancer causes the most cancer-related deaths in the United States, and researchers are searching for new cellular targets to increase survival rates. Inhibiting TGF-β is not ideal because it is critical to normal cellular processes. However, the Moffitt scientists suggest that it may be possible to target the TGF-β-miR183-DAP12 pathway in patients with to activate the immune system and kill cancer cells.

Explore further: Fighting cancer with the immune system

More information: This study appeared online in Proceedings of the National Academy of Sciences on February 28.

Related Stories

Fighting cancer with the immune system

June 11, 2012
The human immune system has a natural ability to identify and attack tumor cells. Natural killer (NK) cells are innate immune cells that are particularly effective at killing tumor cells due to their ability to secrete cytotoxic ...

Cocktail boosts immune cells in fighting cancer

December 6, 2012
Natural killer cells, as part of the body´s immune system, can effectively fight cancer. Unfortunately, they quickly lose their aggressiveness and hence are unable to reject solid tumors. Scientists from the German Cancer ...

Cancer vaccine could use immune system to fight tumors

February 27, 2014
Cincinnati Cancer Center (CCC) and UC Cancer Institute researchers have found that a vaccine, targeting tumors that produce a certain protein and receptor responsible for communication between cells and the body's immune ...

Ovarian cancer cells hijack surrounding tissues to enhance tumor growth

September 4, 2012
Tumor growth is dependent on interactions between cancer cells and adjacent normal tissue, or stroma. Stromal cells can stimulate the growth of tumor cells; however it is unclear if tumor cells can influence the stroma.

Cancer-killing cells controlled by epigenetic process, new study shows

September 23, 2013
Natural killer (NK) cells in the human body can kill and contain viruses and cancerous tumors, and a new study from the University of Southern California (USC) describes for the first time how those cells can be manipulated ...

Patient's own immune cells may blunt viral therapy for brain cancer

November 25, 2012
Doctors now use cancer-killing viruses to treat some patients with lethal, fast-growing brain tumors. Clinical trials show that these therapeutic viruses are safe but less effective than expected.

Recommended for you

T-cells engineered to outsmart tumors induce clinical responses in relapsed Hodgkin lymphoma

January 16, 2018
WASHINGTON-(Jan. 16, 2018)-Tumors have come up with ingenious strategies that enable them to evade detection and destruction by the immune system. So, a research team that includes Children's National Health System clinician-researchers ...

Researchers identify new treatment target for melanoma

January 16, 2018
Researchers in the Perelman School of Medicine at the University of Pennsylvania have identified a new therapeutic target for the treatment of melanoma. For decades, research has associated female sex and a history of previous ...

More evidence of link between severe gum disease and cancer risk

January 16, 2018
Data collected during a long-term health study provides additional evidence for a link between increased risk of cancer in individuals with advanced gum disease, according to a new collaborative study led by epidemiologists ...

Researchers develop a remote-controlled cancer immunotherapy system

January 15, 2018
A team of researchers has developed an ultrasound-based system that can non-invasively and remotely control genetic processes in live immune T cells so that they recognize and kill cancer cells.

Dietary fat, changes in fat metabolism may promote prostate cancer metastasis

January 15, 2018
Prostate tumors tend to be what scientists call "indolent" - so slow-growing and self-contained that many affected men die with prostate cancer, not of it. But for the percentage of men whose prostate tumors metastasize, ...

Pancreatic tumors may require a one-two-three punch

January 15, 2018
One of the many difficult things about pancreatic cancer is that tumors are resistant to most treatments because of their unique density and cell composition. However, in a new Wilmot Cancer Institute study, scientists discovered ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.